Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

Shares of AMAG Pharmaceuticals (NSDQ: AMAG), a pharmaceutical company focusing on maternal medicine, fell below our Sell Stop of $22 and are now rated SELL. The company’s shares tumbled after it announced positive top line results from its Definitive Pharmacokinetic Study for Makena Subcutaneous Administration and will file a New… Read More

It’s time to take profits on Rollins Inc., a stock that seems to be stalling out, and also to clear out the options hanger in order to make room for more opportunities. Rollins . (NYSE: ROL), the global leader in pest control, has exterminated the profit blues for us since we… Read More

I am issuing a Buy recommendation on AMAG Pharmaceuticals (NSDQ: AMAG), a biotech company focusing on improving treatments for common but serious diseases such as complications of pregnancy and anemia. The stock is starting to show signs of accumulation and could deliver a significant intermediate term gain. Buy AMAG Pharmaceuticals up… Read More

I am recommending the purchase of Bristol-Myers Squibb Company (NYSE: BMY) up to $63, a leading global pharmaceutical company with a large oncology presence. The stock is starting to outperform the rest of the big pharma sector which suggests that there is a possible positive surprise in the offing, perhaps… Read More